SCHEMBL3258222

SCHEMBL3258222

O=C(NC1(Cc2ccccc2Cl)CC1)c1ccc(S(=O)(=O)Nc2nccs2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 4/20 0.56
ALOX12 P18054 1/20 0.52
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
ALDH1A1 P00352 3/20 0.49
MAPT P10636 2/20 0.49
MCL1 Q07820 1/20 0.49
LMNA P02545 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CA1 P00915 1/20 0.48
KDM4E B2RXH2 1/20 0.48
USP2 O75604 1/20 0.47
POLB P06746 1/20 0.47
HTT P42858 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
SCN1A P35498 2/20 0.47
SCN8A Q9UQD0 2/20 0.47
AVPR2 P30518 1/20 0.46
GPR27 Q9NS67 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3153389 0.86 ALDH1A1 (0.54) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL3259307 0.85 LMNA (0.60) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL3258616 0.84 SCN3A (0.56) SCN3AALOX12MEN1KMT2AMAPT
SCHEMBL3154212 0.82 SCN3A (0.74) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL3164805 0.81 SCN3A (0.65) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL14777740 0.80 SCN3A (0.56) SCN3AMEN1KMT2AALDH1A1CA1
SCHEMBL3168911 0.79 PTPN1 (0.63) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL3158690 0.78 SCN3A (0.54) SCN3AALOX12MEN1KMT2AALDH1A1
SCHEMBL3161154 0.77 SCN3A (0.62) SCN3AMEN1KMT2AALDH1A1LMNA
SCHEMBL3163449 0.77 SCN3A (0.68) SCN3AALOX12MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741934-B2 Inhibitors of ion channels PFIZER LIMITED (GB) 2014-06-03 US disclosed
US-20130072471-A1 Inhibitors of Ion Channels MARRON BRIAN EDWARD (US) 2013-03-21 US disclosed
US-8357711-B2 Heterocyclic sulfonamides as inhibitors of ion channels PFIZER LIMITED (GB) 2013-01-22 US disclosed
EP-1995241-B1 Inhibitors of ion channels ICAGEN INC (US) 2010-03-17 EP disclosed
US-20090143358-A1 INHIBITORS OF ION CHANNELS ICAGEN, INC. (US) 2009-06-04 US disclosed
EP-1995241-A1 Inhibitors of ion channels ICAgen, Incorporated (US) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072471-A1 Inhibitors of Ion Channels TRPV1, TRPV5, TRPA1 SCN3A 13/4885ALOX12 1302/4885MEN1 4729/4885
US-20090143358-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPV5, TRPA1 SCN3A 13/4885ALOX12 1302/4885MEN1 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.